Start-Up’s Stand-Out Stance On Price
Trek is taking a notably creative approach to finding common ground with payers on pricing, profit and access.
You may also be interested in...
Trek Therapeutics, a three-year old biotech founded by a group of virology veterans, is testing the conventional wisdom in seeking to carve out a potential $17 billion business in the hotly contested hepatitis C space.
In this latest edition of the Lab Links series on notable figures responsible for major advances in drug discovery, In Vivo talks to Harvard Medical School professor and biologist Timothy Springer on his 50-year record as an academic scientist, business entrepreneur and philanthropist. His latest venture is being co-founder – and principal funder – of the independent non-profit Institute for Protein Innovation, an institution designed to fill a critical niche in open-source biomedical research.
Disruptions in the supply/demand configuration of generic drugs have plagued US health care for years. Picket Pharmaceuticals, a new start-up founded by a biostatistician veteran of Africa’s war on HIV, is using the illuminating powers of big data to stabilize the generics supply chain and find untapped areas of value among thousands of products in a business that remains a mystery to physicians, payers and patients alike.